237 related articles for article (PubMed ID: 28231843)
1. High prevalence of quasi-legal psychoactive substance use among male patients in HIV care in Japan: a cross-sectional study.
Hayashi K; Wakabayashi C; Ikushima Y; Tarui M
Subst Abuse Treat Prev Policy; 2017 Feb; 12(1):11. PubMed ID: 28231843
[TBL] [Abstract][Full Text] [Related]
2. Characterizing changes in drug use behaviour following supply shortages of 5-MeO-DIPT, alkyl nitrites and new psychoactive substances among men living with HIV in Japan.
Hayashi K; Wakabayashi C; Ikushima Y; Tarui M
Int J Drug Policy; 2023 Aug; 118():104080. PubMed ID: 37307787
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of, Factors Associated with and Level of Dependence of Psychoactive Substance Use among Mekelle University Students, Ethiopia.
Gebresilassie Tesema A; Hadush Kahsay Z; Gidey Lemma G; Hagos Gebretsadik W; Mussie Weldemaryam M; Gebregiorgis Alemayohu G; L Hackett M
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32013178
[TBL] [Abstract][Full Text] [Related]
4. Recreational drug use and related social factors among HIV-positive men in Japan.
Togari T; Inoue Y; Takaku Y; Abe S; Hosokawa R; Itagaki T; Yoshizawa S; Oki S; Katakura N; Yamauchi A; Wakabayashi C; Yajima T
AIDS Care; 2016 Jul; 28(7):932-40. PubMed ID: 26887351
[TBL] [Abstract][Full Text] [Related]
5. Substance use and sexual behaviours of Japanese men who have sex with men: a nationwide internet survey conducted in Japan.
Hidaka Y; Ichikawa S; Koyano J; Urao M; Yasuo T; Kimura H; Ono-Kihara M; Kihara M
BMC Public Health; 2006 Sep; 6():239. PubMed ID: 17002800
[TBL] [Abstract][Full Text] [Related]
6. Survey of current trends in the abuse of psychotropic substances and plants in Japan.
Kikura-Hanajiri R; Uchiyama N; Goda Y
Leg Med (Tokyo); 2011 May; 13(3):109-15. PubMed ID: 21377397
[TBL] [Abstract][Full Text] [Related]
7. The influence of tightening regulations on patients with new psychoactive substance-related disorders in Japan.
Tanibuchi Y; Matsumoto T; Funada D; Shimane T
Neuropsychopharmacol Rep; 2018 Dec; 38(4):189-196. PubMed ID: 30341809
[TBL] [Abstract][Full Text] [Related]
8. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
Rychert M; Wilkins C; Parker K; Witten K
Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
Gray R; Bressington D; Hughes E; Ivanecka A
J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
[TBL] [Abstract][Full Text] [Related]
10. Limited use of novel psychoactive substances in South London nightclubs.
Wood DM; Hunter L; Measham F; Dargan PI
QJM; 2012 Oct; 105(10):959-64. PubMed ID: 22718853
[TBL] [Abstract][Full Text] [Related]
11. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
Champion KE; Teesson M; Newton NC
Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
[TBL] [Abstract][Full Text] [Related]
12. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries.
Staveteig S; Croft TN; Kampa KT; Head SK
PLoS One; 2017; 12(10):e0186316. PubMed ID: 29023510
[TBL] [Abstract][Full Text] [Related]
13. PSYCHOACTIVE SUBSTANCE USE AMONG NIGERIAN COHORT WITH HIV/AIDS: FREQUENCY, TYPES AND DEMOGRAPHIC CORRELATES.
Olagunju AT; Ogundipe OA; Olagunju TO; Campbell OA; Aina OF; Akanmu AS
Ethiop Med J; 2017 Jan; 55(1):35-41. PubMed ID: 29148637
[TBL] [Abstract][Full Text] [Related]
14. [Factors Related With Psychoactive Substance Use in an Educational Institution in Jamundí Valle, Colombia].
Espinosa Soto K; Hernández Carrillo M; Cassiani CA; Cubides Munevar ÁM; Martínez Cardona Mdel C
Rev Colomb Psiquiatr; 2016; 45(1):2-7. PubMed ID: 26896398
[TBL] [Abstract][Full Text] [Related]
15. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan.
Kikura-Hanajiri R; Kawamura NU; Goda Y
Drug Test Anal; 2014; 6(7-8):832-9. PubMed ID: 24573957
[TBL] [Abstract][Full Text] [Related]
16. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
Rychert M; Wilkins C
Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
[TBL] [Abstract][Full Text] [Related]
18. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
Rychert M; Wilkins C
Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
[TBL] [Abstract][Full Text] [Related]
19. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
[TBL] [Abstract][Full Text] [Related]
20. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
Rychert M; Wilkins C
Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
